Date de publication
Géographie
Langue de la ressource
Texte disponible en version intégrale
Open Access / OK to Reproduce
Évalué par des pairs
L’objectif
This scoping review aimed to evaluate factors associated with Medications for opioid use disorder (MOUD) success during the pregnancy and postpartum period.
Constatations/points à retenir
Data from 15 studies were included. Medications included methadone, naltrexone and buprenorphine (mono or combination therapy). High daily dose of buprenorphine as mono or combination therapy, early initiation and longer duration of MOUD were associated with treatment success. Legal involvement, homelessness, and rural residency were negatively associated with treatment success. There were no differences in outcomes of individuals receiving telemedicine versus in-person care.
La conception ou méthodologie de recherche
A structured search of five research databases was completed. Eligible studies included a metric of success in outpatient treatment in the pregnancy and postpartum period and were conducted in the United States after the Food and Drug Administration’s approval of buprenorphine in 2002. The primary outcome was treatment success (i.e., treatment adherence, abstinence from illegal opioids, or retention in care) during pregnancy and up to 12 months postpartum.
